摘要

<正>The gut microbiome is emerging as a pivotal player in the pathogenesis and development of autoimmune diseases(ADs)[1]. A comprehensive understanding of the interaction among gut microbiota, drug metabolism, and host immune reaction will shed light on the development of precision medicine for ADs. Microbiota-based interventions, such as specific diet, probiotics/prebiotics, or restricted consortium transplantation, have shown promising preventive and therapeutic potentials in pre-clinical and clinical trials [2].